Mattia Rediti
difusion.ulb.ac.be
0000-0002-6713-2599
Université libre de Bruxelles (ULB)
3 papers found
Refreshing results…
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
Characterizing CDK12-Mutated Prostate Cancers
Missing publications? Search for publications with a matching author name.